Arvinas, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-02-02$13.83 RISE2026-02-17$11.44 PEAK2026-03-10$13.83 36d | -17.3% 15d | Missed | Missed | — | — | +20.9% 21d | Missed |
DROP2025-12-08$13.32 RISE2026-01-05$11.17 PEAK2026-02-02$13.83 56d | -16.1% 28d | Missed | Missed | — | — | +23.8% 28d | Missed |
DROP2025-04-30$9.62 RISE2025-08-07$6.24 PEAK2025-10-31$10.14 184d | -35.1% 99d | Missed | Missed | — | — | +62.5% 85d | Missed |
DROP2025-01-03$20.50 RISE2025-05-14$6.07 PEAK2025-07-09$8.23 187d | -70.4% 131d | Missed | Missed | — | — | +35.6% 56d | Missed |
DROP2024-11-29$26.72 RISE2025-04-08$6.19 PEAK2025-04-30$9.62 152d | -76.8% 130d | Missed | Missed | — | — | +55.4% 22d | Missed |
DROP2024-05-22$35.95 RISE2024-09-25$23.66 PEAK2024-11-11$28.04 173d | -34.2% 126d | Missed | Missed | — | — | +18.5% 47d | Missed |
DROP2024-04-09$38.08 RISE2024-08-14$23.81 PEAK2024-11-06$27.99 211d | -37.5% 127d | Missed | Missed | — | — | +17.6% 84d | Missed |
DROP2024-02-26$48.79 RISE2024-07-03$23.90 PEAK2024-07-16$32.73 141d | -51.0% 128d | Missed | Missed | — | — | +36.9% 13d | Missed |
DROP2023-08-31$28.21 RISE2023-10-27$14.19 PEAK2023-12-27$42.33 118d | -49.7% 57d | Missed | Missed | — | — | +198.3% 61d | Missed |
DROP2023-06-13$31.43 RISE2023-07-27$21.92 PEAK2023-08-31$28.21 79d | -30.3% 44d | Missed | Missed | — | — | +28.7% 35d | Missed |
DROP2023-02-07$37.26 RISE2023-06-01$21.73 PEAK2023-06-13$31.43 126d | -41.7% 114d | Missed | Missed | — | — | +44.6% 12d | Missed |
DROP2022-11-15$57.24 RISE2023-03-28$26.15 PEAK2023-06-13$31.43 210d | -54.3% 133d | Missed | Missed | — | — | +20.2% 77d | Missed |
DROP2022-11-15$57.24 RISE2023-01-09$28.58 PEAK2023-02-07$37.26 84d | -50.1% 55d | Missed | Missed | — | — | +30.4% 29d | Missed |
DROP2022-08-10$57.99 RISE2022-10-10$38.79 PEAK2022-11-15$57.24 97d | -33.1% 61d | Missed | Missed | — | — | +47.6% 36d | Missed |
DROP2022-04-21$64.13 RISE2022-08-30$41.87 PEAK2022-11-15$57.24 208d | -34.7% 131d | Missed | Missed | — | — | +36.7% 77d | Missed |
1–15 / 28 1 / 2 | |||||||
NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that employees across Connecticut, in the Greater Boston area, and around the country, took part in the Company’s fourth Arvinas Impact Day this past Friday. This company-wide day of service brings employees together to give back to their communities through volunteer activities that w
Celebrations may be in order for Arvinas, Inc. ( NASDAQ:ARVN ) shareholders, with the analysts delivering a significant...
Celebrations may be in order for Arvinas, Inc. ( NASDAQ:ARVN ) shareholders, with the analysts delivering a significant...
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) for its oral PROTAC drug, VEPPANU (vepdegestrant). This news comes as the...
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) for its oral PROTAC drug, VEPPANU (vepdegestrant). This news comes as the...
Arvinas, Inc. ( NASDAQ:ARVN ) shareholders are probably feeling a little disappointed, since its shares fell 3.8% to...
Arvinas, Inc. ( NASDAQ:ARVN ) shareholders are probably feeling a little disappointed, since its shares fell 3.8% to...
Rigel Pharmaceuticals has entered an exclusive global license agreement with Arvinas and Pfizer to develop, manufacture and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, which was approved in May 2026 following positive Phase 3 VERITAC-2 data. A key nuance is that Rigel assumes worldwide commercialization rights, including the option to sublicense outside the U.S., while Arvinas and...
Rigel Pharmaceuticals has entered an exclusive global license agreement with Arvinas and Pfizer to develop, manufacture and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, which was approved in May 2026 following positive Phase 3 VERITAC-2 data. A key nuance is that Rigel assumes worldwide commercialization rights, including the option to sublicense outside the U.S., while Arvinas and...
Arvinas Inc (NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday. The company posted quarterly losses of 90 cents per share which missed the analyst consensus estimate of losses of 87 cents per share. The company reported quarterly sales of $15.600 million which missed the analyst consensus estimate of $18.097 million. Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) announced that it is entering an exclusive global licensing agreement with Arvinas and Pfizer Inc. (NYSE:PFE) for its
Arvinas Inc (NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday. The company posted quarterly losses of 90 cents per share which missed the analyst consensus estimate of losses of 87 cents per share. The company reported quarterly sales of $15.600 million which missed the analyst consensus estimate of $18.097 million. Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) announced that it is entering an exclusive global licensing agreement with Arvinas and Pfizer Inc. (NYSE:PFE) for its
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO Capital raised the price target for Nextpower Inc (NASDAQ:NXT) from $113 to $125. BMO Capital analyst Ameet Thakkar maintained a Market Perform rating. Nextpower shares closed at $125.37 on Tuesday. See how other analysts view this stock. Baird boosted Aramark (NYSE:ARMK) price target from $50 to $58. Bai
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO Capital raised the price target for Nextpower Inc (NASDAQ:NXT) from $113 to $125. BMO Capital analyst Ameet Thakkar maintained a Market Perform rating. Nextpower shares closed at $125.37 on Tuesday. See how other analysts view this stock. Baird boosted Aramark (NYSE:ARMK) price target from $50 to $58. Bai
Barclays analyst Etzer Darout maintains Arvinas (NASDAQ:ARVN) with a Overweight and raises the price target from $18 to $20.
Pfizer (NYSE:PFE) and Arvinas have transferred global development and commercialization rights for VEPPANU (vepdegestrant) to Rigel Pharmaceuticals. VEPPANU is the first FDA approved PROTAC therapy and was recently cleared in the U.S. for certain patients with advanced breast cancer. The global license agreement makes Rigel the commercial leader for VEPPANU, while Pfizer and Arvinas retain an economic interest through the deal structure. For investors watching NYSE:PFE, this move highlights...
Pfizer (NYSE:PFE) and Arvinas have transferred global development and commercialization rights for VEPPANU (vepdegestrant) to Rigel Pharmaceuticals. VEPPANU is the first FDA approved PROTAC therapy and was recently cleared in the U.S. for certain patients with advanced breast cancer. The global license agreement makes Rigel the commercial leader for VEPPANU, while Pfizer and Arvinas retain an economic interest through the deal structure. For investors watching NYSE:PFE, this move highlights...
BTIG analyst Jeet Mukherjee maintains Arvinas (NASDAQ:ARVN) with a Buy and raises the price target from $16 to $18.
Despite a significant drop in revenue, Arvinas Inc (ARVN) showcases strategic partnerships and cost reductions, maintaining a strong cash position and advancing its clinical pipeline.
Despite a significant drop in revenue, Arvinas Inc (ARVN) showcases strategic partnerships and cost reductions, maintaining a strong cash position and advancing its clinical pipeline.
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call May 12, 2026 8:00 AM EDTCompany ParticipantsJeff Boyle - Vice President of Investor RelationsRandy Teel - CEO,...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ARVN | -14.56% | -32.94% | -24.28% | +24.72% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -17.53% | -27.22% | -20.84% | +12.03% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| DEShaw | quant | 3.64M | $38.57M | 0.02% | Trimmed-1.4% | 2026-03-31 |
| TwoSigma | quant | 1.83M | $19.42M | 0.02% | Added+84.6% | 2026-03-31 |
| StateStreet | passive | 1.83M | $19.38M | 0.00% | Trimmed-0.8% | 2026-03-31 |
| Citadel | multi-strat | 229.8K | $2.44M | 0.00% | Trimmed-90.1% | 2026-03-31 |
| FidelityFMR | fundamental | 88.2K | $935.26K | 0.00% | Added+369.2% | 2026-03-31 |
| TRowePrice | fundamental | 427.1K | $4.53K | 0.00% | Added+423.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | -0.33 | — | — |
| 2026-05-11 | -0.96 | -0.90 | +6.65% |
| 2026-02-24 | -0.57 | -1.10 | -94.32% |
| 2025-11-05 | -0.74 | -0.48 | +35.50% |
| 2025-08-06 | -0.89 | -0.84 | +5.93% |
| 2025-05-01 | -0.97 | 1.14 | +217.57% |
| 2025-02-11 | -0.96 | -0.63 | +34.29% |
| 2024-10-30 | -0.87 | -0.68 | +21.80% |
| 2024-07-30 | -0.59 | -0.49 | +16.58% |
| 2024-05-07 | -1.38 | -0.97 | +29.96% |
| 2024-02-27 | -1.23 | -2.53 | -105.63% |
| 2023-11-07 | -1.58 | -1.18 | +25.48% |
| 2023-08-08 | -1.61 | -1.25 | +22.49% |
| 2023-05-05 | -1.49 | -1.54 | -3.68% |
| 2023-02-23 | -1.10 | -1.56 | -41.24% |
| 2022-11-08 | -1.07 | -1.24 | -15.62% |